Reducing risk, improving outcomes : bioengineering less immunogenic protein therapeutics
One of the great surprises of the biologics revolution has been the discovery that recombinant human proteins, including monoclonals of human origin, can cause immune responses when administered to immune-competent subjects. Preclinical and clinical evaluations of the potential immunogenicity of bio...
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 131(2009), 2 vom: 01. Mai, Seite 189-201 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2009
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Review Recombinant Proteins |
| Accès en ligne |
Volltext |